Loading…
Loading…
Announcements from Anixa Biosciences, published the moment they cross the wire. Get them by email.
2025
Apr 14, 2025
8:00 AM EDT
It has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a new patent application covering its chimeric antigen receptor-T cell (CAR-T) technology.
Apr 09, 2025
8:00 AM EDT
The United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a new patent related to the Company's innovative breast cancer vaccine technology. The patent along with others related to this technology, has been exclusively licensed to Anixa Biosciences, by Cleveland Clinic.
Apr 01, 2025
8:00 AM EDT
Its participation in the Jones Las Vegas Healthcare and Technology Innovation Conference, to be held on April 8-9, 2025 , at The Venetian Resort in Las Vegas, Nevada .
Mar 25, 2025
8:00 AM EDT
It has entered into a letter of intent with VERDI Solutions, GmbH to develop personalized and off-the-shelf peptide vaccines for cancer patients.
Mar 24, 2025
8:00 AM EDT
The United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a key patent application covering its ovarian cancer vaccine technology.
Mar 17, 2025
8:00 AM EDT
Its Chairman and Chief Executive Officer, Dr. Amit Kumar , will be presenting at the 2025 Cancer Advocacy Group of Louisiana ("CAGLA") NeauxCancer Conference taking place on March 27-29, 2025 at the The Roosevelt Hotel in New Orleans .
Mar 10, 2025
8:30 AM EDT
It will host its 2025 Annual Meeting of Stockholders (the "Meeting") on Thursday, March 20, 2025 at 10:00 a.m. Pacific Time in a virtual format.
Mar 03, 2025
8:00 AM EST
Dr. Pam Garzone , Chief Development Officer of Anixa, will be attending the Alliance for Cancer Gene Therapy (ACGT) Summit 2025 and participating as a panelist on the Gynecologic and Breast Cancers panel.
Feb 26, 2025
8:00 AM EST
Has it has dosed its final patient in the third cohort of its ongoing Phase 1 clinical trial evaluating its novel chimeric antigen receptor-T cell (CAR-T) therapy for recurrent ovarian cancer. The study is being conducted through a research partnership with Moffitt Cancer Center ("Moffitt").
Feb 25, 2025
7:30 AM EST
Its breast cancer vaccine was featured on Fox News' "America Reports." The segment highlighted the potential of Anixa's vaccine to revolutionize breast cancer prevention by targeting the disease at its earliest stages.
Feb 24, 2025
8:00 AM EST
Pleased to announce that its pioneering CAR-T therapy for ovarian cancer, developed in collaboration with Moffitt Cancer Center ("Moffitt"), was prominently featured in Breaking Cancer News in an article titled "Navigating Uncharted Territory: CAR-T for Ovarian Cancer."
Feb 18, 2025
8:00 AM EST
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX ), a biotechnology company focused on the treatment and prevention of cancer today announced that it, along with its partner Moffitt Cancer Center ("Moffitt"), has received approval for an amendment to the protocol governing its ongoing clinical trial…
Feb 14, 2025
7:00 AM EST
Its Chairman and CEO, Dr. Amit Kumar , was featured in an interview with Alpha Wolf Trading. In the discussion, Dr. Kumar provided insights into Anixa's groundbreaking CAR-T cell therapy for ovarian cancer and its breast cancer vaccine program, highlighting the Company's innovative approach to immunotherapy and cancer…
Feb 11, 2025
8:30 AM EST
Mike Catelani , President and CFO of Anixa, will be participating in the 18th Annual European Life Sciences CEO Forum taking place February 26-27, 2025 , at the Hilton Zurich Airport Hotel in Zurich, Switzerland .
Feb 04, 2025
8:30 AM EST
Dr. Amit Kumar , Chairman and CEO of Anixa, was featured on CW39's H-Town Live, where he discussed the Company's pioneering efforts in breast cancer prevention.
Jan 21, 2025
8:30 AM EST
The following letter to shareholders from the Company's, Chairman and CEO, Dr. Amit Kumar :
2024
Dec 04, 2024
8:30 AM EST
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX ), a biotechnology company focused on the treatment and prevention of cancer, announced today that it will be participating in the iAccess Alpha Virtual Best Ideas Winter Conference 2024 being held on December 10th and 11th, 2024.
Nov 22, 2024
8:15 AM EST
Its Board of Directors has approved the purchase of Bitcoin as a treasury reserve asset.
Nov 18, 2024
8:20 AM EST
It has dosed its first patient in the third cohort in the ongoing Phase 1 clinical trial of its novel chimeric antigen receptor-T cell (CAR-T) therapy for recurrent ovarian cancer. The study is being conducted through a research partnership with Moffitt Cancer Center ("Moffitt").
Nov 08, 2024
1:17 PM EST
A presentation of new, updated positive data from the Phase 1 clinical trial of its breast cancer vaccine ( NCT04674306 ) at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, being held in Houston, Texas .
